Vir Biotechnology
VIR · Nasdaq · United States
Share price · VIR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VIR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Nov 2026-17.8%
- 9 Nov 2026+11.8%
- 6 Nov 2026+10.8%
- 30 Sep 2026+5.0%
Nothing announced by VIR that day or the session before.
- 1 Sep 2026+6.3%
Nothing announced by VIR that day or the session before.
- 25 Aug 2026+8.1%
Nothing announced by VIR that day or the session before.
- 21 Aug 2026+6.2%
Nothing announced by VIR that day or the session before.
- 6 Aug 2026-3.8%
- 24 Jul 2026-7.0%
- 1 Jul 2026-6.2%
Nothing announced by VIR that day or the session before.
Share of unusual movement by asset
For each asset, the share of VIR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | HBsAgMonoclonal antibody | Hepatitis Delta Chronic Hepatitis Delta |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | -$0.2M | $80M | $228M+ $236M short-term inv. | $96M-$106M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $239M | $135M | $288M+ $250M short-term inv. | —$123M operating cash flow | report ↗ |
| 2026-Q1 | -<$0.1M | $109M | $283M+ $196M short-term inv. | $126M-$132M operating cash flow | report ↗ |
| 2025-Q3 | $0.2M | $151M | $179M+ $328M short-term inv. | $163M-$168M operating cash flow | report ↗ |
| 2025-Q2 | $1.2M | $98M | $306M+ $388M short-term inv. | $111M-$120M operating cash flow | report ↗ |
| 2025-Q1 | $3.0M | $119M | $368M+ $517M short-term inv. | $121M-$78M operating cash flow | report ↗ |
| 2024-Q3 | $2.4M | $195M | $264M+ $741M short-term inv. | $214M-$171M operating cash flow | report ↗ |
| 2024-Q2 | $3.1M | $105M | $317M+ $850M short-term inv. | $138M-$78M operating cash flow | report ↗ |
| 2024-Q1 | $56M | $100M | $180M+ $985M short-term inv. | $65M-$109M operating cash flow | report ↗ |
| 2023-Q3 | $2.6M | $148M | $472M+ $1.2B short-term inv. | $163M-$156M operating cash flow | report ↗ |
| 2023-Q2 | $3.8M | $172M | $687M+ $1.2B short-term inv. | $195M-$389M operating cash flow | report ↗ |
| 2023-Q1 | $63M | $158M | $843M+ $1.4B short-term inv. | $141M-$126M operating cash flow | report ↗ |
| 2022-Q3 | $375M | $114M | $984M+ $1.4B short-term inv. | —$118M operating cash flow | report ↗ |
| 2022-Q2 | -$41M | $115M | $1.5B+ $654M short-term inv. | $76M$960M operating cash flow | report ↗ |
| 2022-Q1 | $1.2B | $90M | $836M+ $400M short-term inv. | —$550M operating cash flow | report ↗ |
| 2021-Q3 | $104M | $99M | $728M+ $56M short-term inv. | —-$106M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $69M | $456M | $241M+ $229M short-term inv. | $110M-$392M operating cash flow | report ↗ |
For fiscal year 2025, Vir Biotechnology reported revenue of $68.56M, down 7.6% YoY. R&D spend was $455.97M, down 10.0% YoY, and the company held $241.07M in cash and equivalents. The net loss for the period was $437.99M.
Vir announced a global strategic collaboration with Astellas to co-develop and co-commercialize VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager targeting PSMA for prostate cancer. Vir will receive $335M in upfront and near-term payments, including $240M in cash, a $75M equity investment at a 50% premium, and a $20M near-term milestone, with eligibility for up to $1.37B in development, regulatory, and sales milestones plus tiered double-digit royalties on ex-U.S. net sales. Development costs will be shared 60% Astellas / 40% Vir, with Astellas leading U.S. commercialization while Vir retains a co-promote option, and Astellas holding exclusive ex-U.S. commercialization rights; updated VIR-5500 Phase 1 data are to be presented at the 2026 ASCO Genitourinary Cancers Symposium.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $74M | $507M | $319M+ $678M short-term inv. | $130M-$446M operating cash flow | report ↗ |
| 2023-FY | $86M | $590M | $261M+ $1.3B short-term inv. | $154M-$779M operating cash flow | report ↗ |
| 2022-FY | $1.6B | $475M | $868M+ $1.5B short-term inv. | —$1.7B operating cash flow | report ↗ |
| 2021-FY | $1.1B | $448M | $363M+ $217M short-term inv. | —-$48M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 33 sales ($8.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-15 | Sabatini Brent · SVP, Chief Accounting Officer | Award / grant | 50,000 | — | — | Form 4 |
| 2026-11-15 | Sawaf Aziz · EVP, Chief Financial Officer | Award / grant | 75,000 | — | — | Form 4 |
| 2026-11-15 | Sawaf Aziz · EVP, Chief Financial Officer | Award / grant (derivative) | 150,000 | — | — | Form 4 |
| 2026-11-03 | de Verneuil Vanina · EVP, General Counsel, Corp Sec | Open-market sale | 2,407 | $11.10 | $27K | Form 4 |
| 2026-11-02 | de Verneuil Vanina · EVP, General Counsel, Corp Sec | Open-market sale | 1,343 | $11.33 | $15K | Form 4 |
| 2026-10-27 | Topalian Suzanne Louise · director | Award / grant | 8,000 | — | — | Form 4 |
| 2026-10-27 | Topalian Suzanne Louise · director | Award / grant | 4,731 | — | — | Form 4 |
| 2026-10-27 | Topalian Suzanne Louise · director | Award / grant (derivative) | 16,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 251 reporting institutions held 140.1M shares ($1.2B, 81.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 17,998,329 | $161.3M |
| 2 | ARCH Venture Management, LLC | 12,916,663 | $115.7M |
| 3 | SB INVESTMENT ADVISERS (UK) LTD | 10,948,093 | $98.1M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 9,215,577 | $82.6M |
| 5 | GSK plc | 8,550,954 | $76.6M |
| 6 | STATE STREET CORP | 7,141,094 | $64.0M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 5,382,103 | $48.2M |
| 8 | GOLDMAN SACHS GROUP INC | 3,250,227 | $29.1M |
| 9 | MORGAN STANLEY | 2,854,205 | $25.6M |
| 10 | ADAR1 Capital Management, LLC | 2,744,714 | $24.6M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2,657,843 | $23.8M |
| 12 | DIMENSIONAL FUND ADVISORS LP | 2,579,678 | $23.1M |
| 13 | CITADEL ADVISORS LLC | 2,098,476 | $18.8M |
| 14 | FMR LLC | 2,071,848 | $18.6M |
| 15 | Soleus Capital Management, L.P. | 2,002,000 | $17.9M |